Jacques Donnez, M.D., Ph.D., Marie-Madeleine Dolmans, M.D., Ph.D., César Diaz, M.D., Ph.D., Antonio Pellicer, M.D., Ph.D.
Volume 104, Issue 5, Pages 1097-1098
In the context of treating cancer, fertility preservation (FP) in young women is a major challenge. Many questions remain because controversial issues still exist (1). Unfortunately, only a small number of patients at risk of premature ovarian failure are referred to FP specialists to discuss different options (1). As reproduction specialists, we consider it vital to provide oncologists, hematologists, and all healthcare providers with accurate information, based on firm evidence, on fertility-sparing treatments, which could potentially have devastating consequences on their future quality of life.
Read the full text at: http://www.fertstert.org/article/S0015-0282(15)01759-8/fulltext